Latest Biotech News

Eli Lilly struck a preclinical acquisition to strengthen non-viral DNA delivery for genetic medicines. Lilly will buy Engage Biologics for up to $202 million, using Engage’s Tethosome platform—a...

Qiagen and Nvidia expanded their partnership to integrate Nvidia computing and BioNeMo into Qiagen Digital Insights biomedical knowledgebases. Qiagen said the aim is to increase AI use in target...

Researchers reported advances in immune-cell engineering that aim to improve the performance of prime editors. In separate work, structure-informed AI and directed evolution were used to redesign...

EpiCypher and New England Biolabs expanded their epigenomics research tool partnership to develop and commercialize CUT&RUN-adjacent workflows. The companies broadened the collaboration to include...

Prism Immersive launched BioSuite Virtual, a mixed-reality training platform designed to teach end-to-end biomanufacturing workflows via a virtual bioreactor. Built with funding from BioMADE and...

Immunovant’s Roivant parent disclosed early Phase 2b open-label results for IMVT-1402, a next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis. The company said 16-week data...

US lawmakers introduced the Enhancing CLIA Act of 2026 to update oversight of laboratory-developed tests (LDTs) after a 2025 court decision said LDTs are medical services and not FDA-regulated...

Parabilis Medicines filed for an IPO days after signing a wide oncology collaboration with Regeneron, aiming to fund Phase 3 development of its Wnt/β-catenin pathway inhibitor zolucatetide for...

Guardant Health has won FDA approval for an upgraded liquid biopsy built to expand the clinical footprint of its Guardant360 test. The agency clearance covers a blood-based comprehensive genomic...

Bristol Myers Squibb and Jiangsu Hengrui have delivered a high-profile licensing alliance that industry sources frame as a turning point for China’s biotech influence. The multibillion-dollar deal...

Eli Lilly moved again in genetic medicine with an all-cash acquisition of Engage Biologics, paying up to $202 million for a non-viral DNA delivery platform. Engage’s preclinical...

Parabilis filed for an initial public offering days after securing a major strategic pact with Regeneron to pursue antibody–peptide conjugates aimed at historically difficult intracellular...

Immunovant’s IMVT-1402 generated a market-moving early readout in difficult-to-treat rheumatoid arthritis. The company disclosed “compelling” initial Phase IIb open-label results for patients with...

The sector’s diagnostics focus intensified with additional evidence that molecular assays are being broadened across the cancer care continuum. Personalis’ Medicare expansion for NeXT Personal in...

U.S. Congressman Neal Dunn introduced the Enhancing CLIA Act of 2026, aiming to update oversight provisions for laboratory-developed tests after a 2025 court decision that treated LDTs as medical...

A multi-agent AI system described as Robin demonstrated an end-to-end workflow for experimental biology, including hypothesis generation, experiment design, and data analysis—then closed the loop...

The WHO declared the ongoing Ebola outbreak caused by the Bundibugyo species a public health emergency of international concern, citing expanding suspected clusters and significant uncertainty...

New evidence in obesity and cardiometabolic risk centered on oral semaglutide’s effects across multiple endpoints in overweight and obese populations. A systematic review and meta-analysis...

Guardant Health secured FDA approval for its upgraded Guardant360 Liquid CDx, a blood-based comprehensive genomic test designed to expand tumor profiling for patients with advanced cancer. The new...

Executives and an academic expert told a biotech forum that recent turmoil and personnel changes at the FDA are raising anxiety among rare-disease drug developers. At the STAT Breakthrough Summit...